G2/M inhibitors that have proven synergistic effects with GBM standard treatments (TMZ and radioitherapy) and other drugs in vitro
| Inhibitor | Target | Synergistic effect | Radiosensitizer | Reference |
| Docetaxel | Microtubules | TMZ | Not tested | 56 |
| BI 2536 | PLK1 | TMZ | Yes | 70,71,221 |
| BI 6727 | PLK1 | TMZ | Not tested | 71,74 |
| GSK461364 | PLK1 | TMZ | Yes | 71,75 |
| GW843682X | PLK1 | TMZ | Not tested | 71 |
| JNJ-10198409 | PLK1 | Not tested | 70 | |
| Abemaciclib | CDK4/6 | TMZ | Not tested | 76,77 |
| Dinaciclib | CDK2/CDK5/ CDK1/CDK9 | Not tested | 79 | |
| Flavopiridol | CDK1/CDK2/CDK4/CDK6 | TMZ | Not tested | 80-83 |
| MK-8776 | CDK2 | Gemcitabine | Not tested | 85 |
| ON123300 | CDK4 | Gefitinib | Not tested | 86 |
| Palbociclib | CDK4/6 | TMZ ; mTOR inhibitor | Yes | 77,87-90 |
| Roscovitine | CDK2/CDK5 | PI3K inhibitor PIK-90 | Not tested | 92,93 |
| Alisertib | AURKA | TMZ | Yes | 97-100 |
| AZD1152 | AURKA/B | TMZ | Yes | 101,102 |
| VX-680 | pan-AURK | Yes | 104 | |
| ZM 447439 | AURKA/B | TMZ | Yes | 106 |
| YM155 | Survivin | TMZ | Yes | 267 |
| M4N | Survivin | TMZ | Yes | 263 |